United States Hypolipidemic Prescription Markets


Regular Price: USD 3,950.00

Special Price USD 2,765.00

30% OFF

* Required Fields

Regular Price: USD 3,950.00

Special Price USD 2,765.00


Be the first to review this product

Table of Contents

United States Hypolipidemic Prescription Markets, Executive SummaryIntroduction to the Hypolipidemic Prescription Market (U.S.) 1996-2006Objectives and PurposeReport Scope and SegmentationMarket Definition Report Structure Patient Population StatisticsSummary of Major FindingsSummary of Major FindingsDrivers Affecting the U.S. Hypolipidemic Prescription MarketRestraints Affecting the U.S. Hypolipidemic Prescription MarketTotal Revenue ForecastsCompetitive AnalysisCompetitive StructureCompetitive FactorsMergers and AcquisitionsUnited States Hypolipidemic Prescription Markets, Market Engineering Research MethodologyResearch ScopeObjectives and PurposeMarket Engineering Forecasting MethodologyOverviewStrategic Significance of the Market Engineering ForecastJudging Credibility and Accuracy of Market Engineering ForecastsForecast AssumptionsGlossary of TermsList of DefinitionsList of AcronymsUnited States Hypolipidemic Prescription Markets, Industry ChallengesIdentification of Challenges Facing the U.S. Hypolipidemic Prescription IndustryIdentification of Challenges Facing the U.S. Hypolipidemic Prescription IndustryInventing New Strategies Prevents Market Share Confiscation from New Market EntrantsPromoting the Benefits of One Drug over Another Raises Market ShareBroadening Indications Stresses the Competitive Advantage of Products to Expand OpportunitiesInfluencing the Composition of Adult Treatment Panel Guidelines Directly Influences Physician Prescription PatternsDetailing the Benefits of Products to Untreated Patients Offers Additional Market OpportunitiesReducing Follow-up Tests Increases Prescription Writing and the Likelihood of Rx to OTC SwitchesPooling Resources in Co-Promotion Alliances Surpasses Marketing Endeavors of Unaccompanied Market PlayersInventing New Strategies Attracts Managed Care Organizations and Generates Greater RevenuesDirecting Research Towards the Benefits of Treating Lipids Other Than LDL Cholesterol Imperils the Statin Drug MarketMaintaining Diligence on Pricing Trends as Patent Expiration Approaches Creates Higher EarningsMarket Engineering Research for the U.S. Hypolipidemic Prescription Market 1996-2006Market Overview and DefinitionsOverviewMarket Definition Scope/SegmentationProduct AnalysisProducts on the MarketResearch Measurement SystemResearch Measurement SystemMarket DriversMarket DriversDirect-to-Consumer Advertising Captures New Patient Targets and Elevates Growth in Penetration RatesExpanding Indications of Hypolipidemic Drugs Identify New Benefits of DrugsPhysician Detailing Educates Benefits of Statin DrugsNew Patient Populations Arise from Direct-to-Consumer AdvertisingAttention Towards HDL as a Preventative Risk Factor Ignites New Promotion StrategiesNovel Approaches to Risk Factors of Cardiovascular Morbidity and Mortality Opens New Opportunities for Statin DrugsNCQA Accreditation Ensures That Drugs Will Increase Revenues of Non-Statin EntitiesManufacturers Support Mass Cholesterol Screening to Identify New Patients and Promote Cholesterol AwarenessDiscoveries in the Benefits of Treating Other Lipids to Reduce One’s Risk for Heart Disease May Open Opportunities for New TherapiesMarket RestraintsMarket RestraintsIntroduction of ZD-4522 in 2001 Confiscates Market Shares of Statin DrugsPatient Noncompliance Disrupts Patient Treatment StrategiesPatent Expiration Poses a Threat to Branded DrugsFrequent Follow-ups May Promote Patient NoncomplianceOpposition to DTC Advertising Stunts Marketing EffortsMedicare Creates Neglected Patient Targets by Limiting Coverage for Routine Cholesterol ScreeningPotential Change of Prognostic Markers of Cardiovascular Disease Shifts Prophylactic Treatment StrategiesOTC Drugs Dislocate Prescribing Trends and Market DistributionNutraceuticals May Compete with Prescription DrugsMarket Engineering Total Revenue Forecasts (2000-2006)Demand AnalysisMarket Engineering and Revenue Forecasts (1996-2006)Major TrendsCompetitive AnalysisCompetitive StructureCompetitive FactorsMarket Share AnalysisMarket Share Winners and WhyMarket Share Losers and WhyMarket Engineering Research for the Emerging U.S. Hypolipidemic Prescription Market Market OverviewMarket OverviewScopeProducts in clinical trialsEmerging Small Molecule TherapiesTechnology TrendsHDL Elevating TherapiesLDL Receptor Based TherapiesEmphasis on Combination Therapy Acceleration Towards Atherogenic FindingsHormone Related Therapy to Improve Lipid ProfileNIH appropriationsNIH appropriationsCompounds Interfering with Cholesterol Absorption and ExcretionLipid FormulationsSaponinsCompounds Near FDA ApprovalZD-4522CholestagelOpportunities for PartnershipOpportunities for PartnershipDiscontinued DevelopmentDiscontinued DevelopmentUnited States Hypolipidemic Prescription Markets, Market Engineering StrategyMarket Engineering Strategic RecommendationsMarket Engineering Strategic RecommendationsCorporate Management Marketing DepartmentResearch and DevelopmentSalesMarket Engineering Awards for the Hypolipidemic Prescription Market (U.S.), 1999Frost & Sullivan's 1999 Market Engineering AwardsFrost & Sullivan's 1999 Market Engineering AwardsMarket Engineering AwardsMarket Engineering AwardsAward Category: Market Engineering LeadershipAward Category: Business Development Strategy Award Category: Entrepreneurial Company

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.